FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017665512> ?p ?o ?g. }

• W3017665512 endingPage "893" @default.
• W3017665512 startingPage "885" @default.
• W3017665512 abstract "Aims: The study evaluated the real-world cost of treatment in multiple sclerosis (MS) patients initiating infused disease-modifying-therapies (DMT) in the United States.Materials and Methods: This retrospective cohort study using administrative claims data included adult patients with MS initiating index infusion DMT (ocrelizumab (OCR), natalizumab (NTZ) or alemtuzumab (ATZ)) from April 2017–September 2018 with 6-months pre/12-months post-index continuous enrollment. The primary cohort included patients who had prescribed annual dosing visits indicated by the approved product label (PL): 3 OCR, 5 ATZ, and 12–13 NTZ infusion visits within the first year of initiation. Annual treatment cost was the sum of all costs on index DMT infusion visit dates. Costs were summarized for a primary and secondary cohort of patients receiving additional doses than prescribed in PL (>3 OCR, >5 ATZ, and >13 NTZ infusion visits); and an overall cohort of patients who met minimum required annual dose (≥3 OCR, ≥5 ATZ, and ≥12 NTZ), further stratified by insurance type.Results: For patients in the primary cohort (123 OCR, 18 ATZ, and 48 NTZ), mean (standard-deviation) annual cost of treatment with OCR, ATZ, and NTZ cohorts was $72,066 ($34,480), $121,053 ($51,097) and $93,777 ($38,815), respectively. Among patients initiating OCR and NTZ, 15 and 6% respectively, had additional infusion visits leading to greater costs. Mean annual costs of index infusion DMT treatment in the overall cohort (162 patients treated with OCR, 18 with ATZ, 56 with NTZ) were $80,582, $121,053, and $93,807, respectively. The mean costs for commercial enrollees were higher than those for MAPD enrollees.Limitations: Small sample size, limited population generalizability, and cost-reduction for ATZ beyond the second year need to be accounted for.Conclusions: Real-world infusion DMT treatment costs for commercially insured patients were higher than perceived expenditures based on wholesale acquisition cost and administration costs via a physician-fee schedule. Consideration of real-world costs in cost-effectiveness and treatment/coverage decisions is needed." @default.
• W3017665512 created "2020-05-01" @default.
• W3017665512 creator A5011695068 @default.
• W3017665512 creator A5023283071 @default.
• W3017665512 creator A5026232658 @default.
• W3017665512 creator A5070542699 @default.
• W3017665512 creator A5076698407 @default.
• W3017665512 creator A5088161063 @default.
• W3017665512 date "2020-05-18" @default.
• W3017665512 modified "2023-10-12" @default.
• W3017665512 title "Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States" @default.
• W3017665512 cites W1970693461 @default.
• W3017665512 cites W2014094373 @default.
• W3017665512 cites W2116503253 @default.
• W3017665512 cites W2132555717 @default.
• W3017665512 cites W2156052776 @default.
• W3017665512 cites W2258401109 @default.
• W3017665512 cites W2293924143 @default.
• W3017665512 cites W2734537819 @default.
• W3017665512 cites W2734919224 @default.
• W3017665512 cites W2793126111 @default.
• W3017665512 cites W2906091091 @default.
• W3017665512 cites W4211254511 @default.
• W3017665512 doi "https://doi.org/10.1080/13696998.2020.1761821" @default.
• W3017665512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32338098" @default.
• W3017665512 hasPublicationYear "2020" @default.
• W3017665512 type Work @default.
• W3017665512 sameAs 3017665512 @default.
• W3017665512 citedByCount "7" @default.
• W3017665512 countsByYear W30176655122021 @default.
• W3017665512 countsByYear W30176655122022 @default.
• W3017665512 countsByYear W30176655122023 @default.
• W3017665512 crossrefType "journal-article" @default.
• W3017665512 hasAuthorship W3017665512A5011695068 @default.
• W3017665512 hasAuthorship W3017665512A5023283071 @default.
• W3017665512 hasAuthorship W3017665512A5026232658 @default.
• W3017665512 hasAuthorship W3017665512A5070542699 @default.
• W3017665512 hasAuthorship W3017665512A5076698407 @default.
• W3017665512 hasAuthorship W3017665512A5088161063 @default.
• W3017665512 hasBestOaLocation W30176655121 @default.
• W3017665512 hasConcept C126322002 @default.
• W3017665512 hasConcept C167135981 @default.
• W3017665512 hasConcept C2777288759 @default.
• W3017665512 hasConcept C2779134260 @default.
• W3017665512 hasConcept C2781004633 @default.
• W3017665512 hasConcept C71924100 @default.
• W3017665512 hasConcept C72563966 @default.
• W3017665512 hasConceptScore W3017665512C126322002 @default.
• W3017665512 hasConceptScore W3017665512C167135981 @default.
• W3017665512 hasConceptScore W3017665512C2777288759 @default.
• W3017665512 hasConceptScore W3017665512C2779134260 @default.
• W3017665512 hasConceptScore W3017665512C2781004633 @default.
• W3017665512 hasConceptScore W3017665512C71924100 @default.
• W3017665512 hasConceptScore W3017665512C72563966 @default.
• W3017665512 hasIssue "8" @default.
• W3017665512 hasLocation W30176655121 @default.
• W3017665512 hasOpenAccess W3017665512 @default.
• W3017665512 hasPrimaryLocation W30176655121 @default.
• W3017665512 hasRelatedWork W2076573529 @default.
• W3017665512 hasRelatedWork W2603773853 @default.
• W3017665512 hasRelatedWork W2847517984 @default.
• W3017665512 hasRelatedWork W3139694002 @default.
• W3017665512 hasRelatedWork W3194305838 @default.
• W3017665512 hasRelatedWork W3204242621 @default.
• W3017665512 hasRelatedWork W4205894869 @default.
• W3017665512 hasRelatedWork W4286210782 @default.
• W3017665512 hasRelatedWork W4322724425 @default.
• W3017665512 hasRelatedWork W3087476458 @default.
• W3017665512 hasVolume "23" @default.
• W3017665512 isParatext "false" @default.
• W3017665512 isRetracted "false" @default.
• W3017665512 magId "3017665512" @default.
• W3017665512 workType "article" @default.